You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. DEVELOPMENT OF NOVEL AMINOGLYCOSIDE POLYMERS AND NANOPARTICLES FOR NUCLEIC ACID DELIVERY IN CHRONIC WOUNDS

    SBC: Synergyan, LLC            Topic: NCATS

    PROJECT SUMMARYThe purpose of this Phase I STTR project is to develop targeted nanoparticles for the combinatorial delivery of nucleic acids and small molecule drugs as therapeutics. We have previously developed a library of novel aminoglycoside-derived polymer nanoparticles capable of simultaneously delivering nucleic acids and small molecule drugs or imaging agents into mammalian cells. The effi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR) from a nuclear incident. The pathobiology of radiation pneumonitis and radiation-induced lung fibrosis (RILF) is complex but includes the deleterious effects of unchecked inflammation (reactive oxyg ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. The MICELI Aggregometer: a Point-of-Care Platelet Function Analyzer

    SBC: PLAKDX, LLC            Topic: NHLBI

    PROJECT SUMMARY: While platelets are vital blood cells to maintain vascular integrity and foster tissue repair, unfortunately they may become “inappropriately” activated in a wide range of disease states. To reduce this activation risk anti- thrombotic drugs are routinely prescribed to an ever increasing variety of patients, in fact being leading agents prescribed by physicians today. While th ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    Mortality rates in intensive care units (ICUs) are unacceptably high and are directly related to the duration of mechanical ventilation that is required to support patients with respiratory failure. For example, acute respiratory distress syndrome (ARDS) is a vexing acute inflammatory lung disease requiring mechanical ventilatory support as the result of severe hypoxemia and respiratory failure. T ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Development of surfactant protein A-derived peptidomimetics for the treatment of asthma

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. There is no current innate immune modulator for the treatment of asthma. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. The cause of an exacerbation is of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP)

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NICHD

    ABSTRACT: Intrauterine infection and chorioamnionitis are common complications of pregnancy associated with significant maternal, perinatal, and long-term adverse outcomes. Adverse maternal outcomes include postpartum infections and sepsis while adverse infant outcomes include stillbirth, premature birth, neonatal sepsis, chronic lung disease and brain injury leading to cerebral palsy and other ne ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic targeting of Nox2 and Nox4 in Duchenne Muscular Dystrophy

    SBC: Fibronox            Topic: NHLBI

    ABSTRACT: Duchenne muscular dystrophy (DMD) caused by a genetic mutation that prevents the production of dystrophin, a protein that muscles need to work properly. DMD patients exhibit progressive muscle weakness occurs in both skeletal and cardiac muscle. Cardiac fibrosis is ultimately the leading cause of their premature death. There is no cure for DMD, thus it remains an unmet medical need. Any ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Surface-covering gels for broad-spectrum antimicrobial protection following open

    SBC: SONORAN BIOSCIENCES INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): About 3-4% of all fractures are estimated to be open fractures, where the fracture is exposed through defects in the skin and soft tissues. This equates to about 250,000 open fractures in the United States annually. Open fractures present a high risk of infection. Infection results in considerable financial burden to both the patient an healthcare system, requ ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Slip Flow Chromatography

    SBC: BIOVIDRIA, INC.            Topic: 100

    DESCRIPTION provided by applicant The goal of this STTR Phase II collaboration between Purdue University and bioVidria Inc is to commercialize disruptive new technology for protein chromatography and then maximize its impact by serving the fastest growing segment of the pharmaceutical industry protein drugs The product is a reversed phase chromatography column that uses silica particles of ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)

    SBC: IRON HORSE DIAGNOSTICS, INC.            Topic: 101

    DESCRIPTION provided by applicant Amyotrophic lateral sclerosis ALS or Lou Gehrigandapos s disease is a fatal neurodegenerative disease with a typical lifespan of years after diagnosis The initial symptoms can be similar to many other neurologic disorders and often begin with limb weakness muscle fasciculations or increasing difficulties in speech or breathing No definitive diagnost ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government